Pediatric growth hormone deficiency

The approved past: sermorelin’s strongest, and oldest, direct evidence

The one setting where sermorelin trial data ever supported an approved indication is pediatric growth hormone deficiency. That is what Geref was licensed for, and the pivotal open-label trial showed children growing faster on nightly sermorelin than they had before treatment. Small adult trials exist too, and the adult-use unit reads them closely, but none of them anchored an approval anywhere.

This unit covers what pediatric GHD is, the Geref trial that anchors the evidence, the approval and the 2008 discontinuation that ended it, and why recombinant GH ultimately took over the indication.